Company profile
PROTAGONIST THERAPEUTICS, INC
NASDAQ:PTGXBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| RUSFERTIDE | phase3 | — | 7 | active |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (13)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05210790 | phase3 | active_not_recruiting | 2022-04-01 | 2025-02-21 | Protagonist Therapeutics, Inc. | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera |
| NCT04057040 | phase2 | completed | 2019-10-01 | 2023-02-14 | Protagonist Therapeutics, Inc. | Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE) |
| NCT04504383 | phase2 | completed | 2020-08-05 | 2023-02-16 | Protagonist Therapeutics, Inc. | PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC) |
| NCT04767802 | phase2 | completed | 2021-02-02 | 2023-03-15 | Protagonist Therapeutics, Inc. | PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit |
| NCT04202965 | phase2 | completed | 2020-03-19 | 2021-10-06 | Protagonist Therapeutics, Inc. | PTG-300 in Subjects With Hereditary Hemochromatosis |
FDA applications (0)
No records yet.